Clinical trial
Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma: a Single Arm, Multicentre Trial.
NCT04063683 is registered in ClinicalTrials.gov with Henan Cancer Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma: a Single Arm, Multicentre Trial.
- Lead sponsor
- Henan Cancer Hospital
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- October 7, 2019
- Completion date
- June 30, 2022
- Enrollment
- 47 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.